CGON Form 4 shows 20,889 director stock options granted

Rhea-AI Filing Summary

CG Oncology, Inc. (CGON) disclosed a new stock option grant to a director. On 11/24/2025, the reporting person received a director stock option to purchase 20,889 shares of CG Oncology common stock at an exercise price of $43.56 per share. The option expires on 11/23/2035 if not exercised.

According to the vesting terms, 1/36th of the shares subject to the option vest monthly following November 24, 2025, as long as the director continues to provide service to the company through each vesting date. After this grant, the reporting person beneficially owns 20,889 derivative securities directly in the form of these stock options.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Rossi Christina

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (right to buy)	20,889	$0.00	--

Holdings After Transaction: Director Stock Option (right to buy) — 20,889 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rossi Christina

(Last) (First) (Middle)

C/O CG ONCOLOGY, INC.

400 SPECTRUM CENTER DRIVE, SUITE 2040

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CG Oncology, Inc. [ CGON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (right to buy)	$43.56	11/24/2025		A		20,889		(1)	11/23/2035	Common Stock	20,889	$0	20,889	D

Explanation of Responses:

1. 1/36th of the shares subject to the option vest monthly following November 24, 2025, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

	/s/ Joshua Patterson, Attorney-in-Fact for Christina Rossi	11/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CG Oncology (CGON) report in this Form 4?

CG Oncology reported a director stock option grant for 20,889 options to purchase its common stock, awarded on 11/24/2025.

What is the exercise price of the new CG Oncology (CGON) director stock options?

The director stock options have an exercise price of $43.56 per share for CG Oncology common stock.

When do the CG Oncology (CGON) director stock options vest?

The options vest as 1/36th of the shares each month following November 24, 2025, subject to the director’s continuous service.

When do the CG Oncology (CGON) director stock options expire?

The reported director stock options expire on 11/23/2035 if they are not exercised before that date.

How many CG Oncology (CGON) derivative securities does the director own after this transaction?

After this transaction, the director beneficially owns 20,889 derivative securities, all in the form of stock options, held directly.

What role does the reporting person have at CG Oncology (CGON)?

The reporting person is identified as a Director of CG Oncology, Inc.